Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 51 Show results per page	View Search Criteria \| Help With Results

Last Modified: 5/9/2007 First Published: 5/28/2004


1.		Phase III Randomized Study of Paclitaxel With or Without GW572016 as First-Line Therapy in Women With Advanced or Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				GSK-EGF30001 NCT00075270

Last Modified: 8/10/2007 First Published: 6/23/2004


2.		Phase III Randomized Study of Capecitabine With Versus Without Lapatinib in Women With Refractory Locally Advanced or Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				GSK-EGF100151 UCLA-0403074-01, NCT00078572


3.		Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				Pharmaceutical / Industry				EGF104900 NCT00320385


4.		Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				EGF105485 NCT00374322


5.		Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From China

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				EGF109491 NCT00508274

Last Modified: 11/7/2007 First Published: 11/22/2004


6.		Phase I/II Study of Lapatinib in Patients With Recurrent Malignant Glioblastoma Multiforme

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over				NCI				CAN-NCIC-IND170 NCIC-170, NCT00099060, IND170


7.		Lapatinib/Carboplatin/Paclitaxel in Previously Treated Ovarian or Breast Cancer Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				Other				CRC 0503 NCT00316407


8.		GW572016 Combined With Trastuzumab For The Treatment Of Previously Trastuzumab-Treated Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				20 to 74				Pharmaceutical / Industry				EGF105635 NCT00371488

Last Modified: 11/6/2008 First Published: 7/6/2007


9.		Phase I/II Study of Neoadjuvant Induction Chemotherapy Comprising Docetaxel, Cisplatin, and Fluorouracil Followed by Chemoradiotherapy Comprising Carboplatin and Radiation Therapy With or Without Lapatinib Ditosylate in Patients With Locally Advanced Squamous Cell Carcinoma of the Larynx or Hypopharynx

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Treatment				Closed				Over 18				Other, Pharmaceutical / Industry				EORTC-24051 EORTC-24051, EUDRACT-2006-002667-33, GSK-EORTC-24051, NCT00498953

Last Modified: 9/28/2006 First Published: 12/21/2002


10.		Phase II Study of GW572016 in Women With Advanced or Metastatic Breast Cancer Refractory to First-Line Trastuzumab (Herceptin) and Chemotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				UCLA-0208079 GSK-EGF20002, NCT00051103

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute